Patents Represented by Attorney Michelle A. Cepeda

Find this attorney in the Justia Lawyer Directory

  • Rebeccamycin
    Patent number: 5158938
    Abstract: Addition of bromine to the culture medium during fermentation of a rebeccamycin-producing strain of Saccharothrix aerocolonigenes results in production of a new rebeccamycin derivative having advantageous antineoplastic properties.
    Type: Grant
    Filed: September 23, 1991
    Date of Patent: October 27, 1992
    Assignee: Bristol-Myers Squibb Company
    Inventors: Kin S. Lam, Daniel R. Schroeder, Jacqueline Mattei, James A. Matson, Salvatore Forenza
  • BU-4164E - A and B, prolyl endopeptidase inhibitors and their methods of use
    Patent number: 5073549
    Abstract: Disclosed herein are antibiotic BU-4164E A and B isolated from Streptomyces sp. These compounds are prolyl endopeptidase inhibitors.
    Type: Grant
    Filed: October 4, 1990
    Date of Patent: December 17, 1991
    Assignee: Bristol-Myers Squibb Company
    Inventors: Soichiro Toda, Yasutaro Hamagishi, Toshikazu Oki, Koji Tomita
  • 5-HT.sub.3 antagonists: use in reducing opiate tolerance
    Patent number: 5057519
    Abstract: The use of 5-HT.sub.3 antagonists and their pharmaceutically acceptable salts in reducing tolerance to opiates in particular morphine.
    Type: Grant
    Filed: June 11, 1990
    Date of Patent: October 15, 1991
    Assignee: Bristol-Myers Squibb Company
    Inventor: Stacy N. Suberg
  • BU-4164E - A and B, prolyl endopeptidase inhibitors
    Patent number: 4999349
    Abstract: Disclosed herein are antibiotic BU-4164E A and B isolated from Streptomyces sp. These compounds are prolyl endopeptidase inhibitors.
    Type: Grant
    Filed: March 22, 1990
    Date of Patent: March 12, 1991
    Assignee: Bristol-Myers Squibb Co.
    Inventors: Soichiro Toda, Yasutaro Hamagishi, Toshikazu Oki, Koji Tomita
  • Drug-monoclonal antibody conjugates
    Patent number: 4952394
    Abstract: There is disclosed a drug-monoclonal antibody conjugate wherein the antibody is linked to a antitumor drug using disulfide benzyl carbamate or carbonate as the linker. Also disclosed is a method of delivering an active antitumor drug to the site of tumor cells in a mammal by administering the drug-monoclonal antibody conjugate.
    Type: Grant
    Filed: November 23, 1987
    Date of Patent: August 28, 1990
    Assignee: Bristol-Myers Company
    Inventor: Peter D. Senter
  • High percentage .beta.-yield synthesis of carbapenem intermediates
    Patent number: 4895939
    Abstract: Disclosed herein is a novel high .beta.-yield producing novel intermediates of the formula ##STR1## where R.sup.4 is ##STR2## useful in the synthesis of 1-.beta.-alkyl carbapenems.
    Type: Grant
    Filed: June 14, 1988
    Date of Patent: January 23, 1990
    Assignee: Bristol-Myers Company
    Inventors: Alain Martel, Jean-Paul Daris, Jacques Corbeil